Nomenclature
CAS number: 2030-63-9
N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; 3-(
p-chloroanilino)-10-(
p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 2-(4-chloroanilino)-3-isopropylimino-5-(4-chlorophenyl)-3,5-dihydrophenazine; 2-
p-chloroanilino-5-
p-chlorophenyl-3,5-dihydro-3-isopropyliminophenazine; G-30320; B-663; Lampren(e) (Novartis).
C
27H
22Cl
2N
4; mol wt 473.40.
C 68.50%, H 4.68%, Cl 14.98%, N 11.83%.
Description and references
Prepn: V. C. Barry et al., US 2948726 (1960 to Geigy); Barry et al., Nature 179, 1013 (1957); Barry et al., J. Chem. Soc. 1958, 859; Belton et al., Proc. R. Irish Acad. Sect.
B 62, 9 (1961), C.A. 58, 4556d (1963). Activity studies: Vischer, Arzneim.-Forsch. 18, 1529 (1968).
HPLC determn in plasma: J. H. Peters et al., J. Chromatogr. 229, 503 (1982).
Toxicity data: Stenger et al., Arzneim.-Forsch. 20, 794 (1970). Clinical
studies: Mathies, ibid. 1838; Karat et al., Br. Med. J. 1, 198
(1970). Review of clinical pharmacokinetics: M. R. Holdiness, Clin. Pharmacokinet. 16, 74-85
(1989); of clinical use: J. C. Garrelts, DICP Ann. Pharmacother. 25, 525-531 (1991).
Comprehensive description: V. K. Kapoor, Anal. Profiles Drug Subs. 18, 91-120 (1989);
C. M. O'Driscoll, O. I. Corrigan, Anal. Profiles
Drug Subs. Excip. 21, 75-108 (1992).
Properties
Dark-red crystals, mp 210-212°. uv max (0.01M methanolic HCl): 284, 486 nm (abs. ≈1.30, ≈0.64). pKa 8.37; also reported
as 8.51. Sol in dil acetic acid,
DMF. Sol in 15 parts of chloroform, 700 parts of ethanol, 1000 parts
of ether. Practically insol in water. Log
P (octanol/water): 7.48; (isooctane/pH 5.15 buffer) at 20°: 5.01; (n-octanol/pH 5.15 buffer) at 20°: 4.30; (n-octanol/pH
5.15 buffer) at 37°: 4.40;
(n-octanol/pH 5.15 buffer) at
45°: 4.48; (n-octanol/pH 5.15 buffer) at 55°: 4.54. LD50 orally in mice, rats, and guinea pigs: >4 g/kg (Stenger).Therapeutic Category
Antibacterial (tuberculostatic, leprostatic).
Keywords
Antibacterial (Leprostatic); Antibacterial (Tuberculostatic)